Compare AGPU & NVNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AGPU | NVNO |
|---|---|---|
| Founded | 2002 | 1987 |
| Country | United States | United States |
| Employees | 24 | 37 |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.9M | 7.2M |
| IPO Year | N/A | N/A |
| Metric | AGPU | NVNO |
|---|---|---|
| Price | $1.43 | $12.01 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 42.0K | 13.8K |
| Earning Date | 03-27-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $486.27 | N/A |
| Revenue Next Year | $65.50 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.25 | $0.30 |
| 52 Week High | $9.00 | $12.85 |
| Indicator | AGPU | NVNO |
|---|---|---|
| Relative Strength Index (RSI) | 30.67 | 54.54 |
| Support Level | N/A | $0.49 |
| Resistance Level | $2.83 | $12.69 |
| Average True Range (ATR) | 0.21 | 1.11 |
| MACD | 0.05 | -0.14 |
| Stochastic Oscillator | 20.51 | 49.35 |
Axe Compute Inc functions as an active infrastructure operator. The company intends to expand access to AI compute resources by utilizing the Aethir network, which provides scalable, cost-efficient cloud GPU services for AI, machine learning, gaming, and rendering applications. Through the use of Aethir's decentralized international infrastructure, it aims to provide access to bare-metal GPUs at scale for both emerging and established organizations. It plans to monetize access to the network by serving enterprise customers that require guaranteed capacity, service-level agreements, and a counterparty operating within conventional corporate and regulatory frameworks.
enVVeno Medical Corp is a late clinical-stage medical device company focused on advancing bioprosthetic (tissue-based) solutions to improve the standard of care for treating venous disease. The company's product, VenoValve, is a surgical replacement venous valve that is currently being evaluated in a U.S. pivotal study. The company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the products are designed to act as one-way valves to help assist in propelling blood up the veins of the leg, and back to the heart and lungs. The company has determined that it currently operates in a single segment, Medical Device development, located in a single geographic location, the United States.